Zoetis Inc. $ZTS Shares Acquired by Ninety One UK Ltd

Ninety One UK Ltd lifted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 2.4% during the fourth quarter, Holdings Channel reports. The fund owned 1,146,126 shares of the company’s stock after purchasing an additional 26,994 shares during the quarter. Ninety One UK Ltd’s holdings in Zoetis were worth $144,206,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Halbert Hargrove Global Advisors LLC lifted its position in Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after buying an additional 144 shares during the period. Global Wealth Strategies & Associates purchased a new position in Zoetis during the fourth quarter worth about $25,000. Lodestone Wealth Management LLC purchased a new position in Zoetis during the fourth quarter worth about $30,000. KERR FINANCIAL PLANNING Corp purchased a new position in Zoetis during the third quarter worth about $31,000. Finally, Holos Integrated Wealth LLC purchased a new position in Zoetis during the fourth quarter worth about $32,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. Piper Sandler reiterated a “neutral” rating and set a $135.00 target price (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. BTIG Research reiterated a “buy” rating and set a $160.00 target price on shares of Zoetis in a research report on Thursday, February 26th. UBS Group set a $136.00 price objective on Zoetis in a report on Thursday, January 29th. Finally, Citigroup assumed coverage on Zoetis in a report on Wednesday. They issued a “buy” rating and a $145.00 price objective on the stock. Seven equities research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Zoetis has a consensus rating of “Hold” and a consensus target price of $152.25.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $122.39 on Friday. The company has a market cap of $51.48 billion, a P/E ratio of 20.33, a PEG ratio of 1.82 and a beta of 0.98. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. Zoetis Inc. has a one year low of $113.29 and a one year high of $172.23. The business’s 50-day simple moving average is $121.73 and its 200 day simple moving average is $126.50.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. The business had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company’s revenue was up 3.0% on a year-over-year basis. During the same period last year, the business posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.